The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
Postmenopausal women, and men, with hormone receptor-positive, HER2-negative, locally advanced or metastatic BC with a PIK3CA mutation after disease progression following ET as monotherapySOLAR-1
Breast Cancer
Breast Cancer
PIK3CA-mutated HR+ HER2-
SOLAR-1
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Trastuzumab deruxtecan
-
Single arm study (Phase II)
HER2-positive breast cancer that is metastatic (has spread to other parts of the body) or cannot be removed by surgery. HER2-positive means that the cancer cells produce a protein called HER2 in large quantities on their surface, which makes the tumour cells grow more quickly. Used on its own in patients who have received one or more HER2-targeted treatmentsDESTINY-Breast01
Breast Cancer
Breast Cancer
HER2+
DESTINY-Breast01
2
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
2
Talazoparib
-
Standard chemotherapy
Post anathacycline and taxaneEMBRACA
Breast Cancer
Breast Cancer
HER2- g-BrCa+ve
EMBRACA
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Olaparib
-
Standard chemotherapy
Patients with HER2-negative locally advanced or metastatic BC who have been previously treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless unsuitable for these treatmentsOlympiAD
Breast Cancer
Breast Cancer
HER2- g-BrCa+ve
OlympiAD
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Tucatinib
Trastuzumab + capecitabine
Placebo, trastuzumab + capecitabine
HER2-positive locally advanced or metastatic breast cancer after at least 2 prior anti-HER2 treatment regimes HER2CLIMB
Breast Cancer
Breast Cancer
HER2+
HER2CLIMB
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Binimetinib
Encorafenib
Vemurafenib
In combination with encorafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutationCOLUMBUS
Skin Cancers
Cutaneous Melanoma
BRAF V600
COLUMBUS
A
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a/F1
5
A
Ramucirumab
Erlotinib
Placebo + Erlotinib
First-line treatment of NSCLC with EGFR mutationRELAY
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
RELAY
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Durvalumab
-
Placebo
Treatment of adult patients with unresectable, stage III NSCLC whose disease has not progressed following concurrent platinum-based CRTPACIFIC
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1
PACIFIC
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Atezolizumab
Nab-paclitaxel
Placebo + nab-paclitaxel
In combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumours have PD-L1 expression ≥1% and who have not received prior ChT for metastatic disease.IMpassion130
Breast Cancer
Breast Cancer
Triple-negative PD-L1+≥1%
IMpassion130
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Dab/Tram (dabrafenib and trametinib)
-
Placebo
In combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resectionCOMBI-AD
Skin Cancers
Cutaneous Melanoma
BRAF V600
COMBI-AD
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
FINAL SCORE
F1
A
Pembrolizumab
-
Placebo
Adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma and who have undergone complete resectionKEYNOTE-054
Skin Cancers
Cutaneous Melanoma
-
KEYNOTE-054
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
FINAL SCORE
F1
A
Nivolumab
-
Ipilimumab 10mg/kg
Adjuvant treatment of adults and adolescents 12 years of age and older with Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resectionCheckMate 238
Skin Cancers
Cutaneous Melanoma
-
CheckMate 238
C
PRELIMINARY SCORE
RFS
ADJUSTMENTS
FINAL SCORE
F1
C
Abiraterone
Prednisone + ADT (androgen deprivation therapy)
ADT + placebo
Indicated with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)LATITUDE
Genitourinary Cancers
Prostate cancer
-
LATITUDE
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Apalutamide
ADT (androgen deprivation therapy)
ADT + placebo
Treatment of non metastatic castration resistant prostate cancer (nmCRPC) in adult men who are at high risk of developing metastatic diseaseSPARTAN
Genitourinary Cancers
Prostate cancer
-
SPARTAN
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Abiraterone
Prednisone + ADT (androgen deprivation therapy)
ADT + placebo
Indicated with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)STAMPEDE
Genitourinary Cancers
Prostate cancer
-
STAMPEDE
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Enzalutamide
ADT (androgen deprivation therapy)
ADT
Treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapyENZAMET
Genitourinary Cancers
Prostate cancer
-
ENZAMET
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Enzalutamide
ADT (androgen deprivation therapy)
ADT + placebo
Treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC)PROSPER
Genitourinary Cancers
Prostate cancer
-
PROSPER
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Docetaxel
ADT (androgen deprivation therapy)
ADT
In combination with androgen-deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancerCHAARTED
Genitourinary Cancers
Prostate cancer
-
CHAARTED
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Docetaxel
ADT (androgen deprivation therapy)
ADT
In combination with androgen-deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer.CHAARTED
Genitourinary Cancers
Prostate cancer
-
CHAARTED
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Docetaxel
ADT (androgen deprivation therapy)
ADT
In combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancerSTAMPEDE
Genitourinary Cancers
Prostate cancer
-
STAMPEDE
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Darolutamide
ADT (androgen deprivation therapy)
ADT + placebo
Non-metastatic castration resistant prostate cancer for adult men who are at high risk of developing metastatic diseaseARAMIS
Genitourinary Cancers
Prostate cancer
-
ARAMIS
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Apalutamide
ADT (androgen deprivation therapy)
ADT + placebo
In adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).TITAN
Genitourinary Cancers
Prostate cancer
-
TITAN
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pasireotide
-
Single arm
Advanced carcinoids of the lung and thymusLUNA
Endocrine Tumours
Neuroendocrine Tumour - Lung and thymic carcinoids
-
LUNA
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F3
3
Everolimus
-
Single arm
Unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive diseaseLUNA
Endocrine Tumours
Neuroendocrine Tumour - Lung and thymic carcinoids
-
LUNA
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F3
3
Everolimus
Pasireotide
Single arm
Advanced carcinoids of the lung and thymusLUNA
Endocrine Tumours
Neuroendocrine Tumour - Lung and thymic carcinoids
-
LUNA
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F3
2
Cetuximab
Cisplatin or carboplatin plus 5-FU
Cisplatin or carboplatin plus 5-FU
Treatment of patients with squamous cell cancer of the head and neck in combination with platinum-based chemotherapy for recurrent and/or metastatic diseaseEXTREME
Head and neck cancer
Squamous cell
-
EXTREME
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Nivolumab
-
Investigator choice (methotrexate or cetuximab or docetaxel)
As monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapyCheckMate141
Head and neck cancer
Squamous cell
-
CheckMate141
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Rucaparib
-
Single arm (Phase II)
Platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. ARIEL2
Gynaecological Malignancies
Ovarian, fallopian tubes and peritoneum cancer
BRCA mutation
ARIEL2
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Rucaparib
-
Placebo
Maintenance treatment of patients with platinum sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapyARIEL3
Gynaecological Malignancies
Ovarian, fallopian tubes and peritoneum cancer
Homologous recombination deficiencies (HRD) (BRCA mutant or BRCA wild-type and high loss of heterozygosity)
ARIEL3
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Rucaparib
-
Placebo
Maintenance treatment of patients with platinum sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapyARIEL3
Gynaecological Malignancies
Ovarian, fallopian tubes and peritoneum cancer
Germline or somatic - BRCA mutation
ARIEL3
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.